Emergent Biosolutions, Inc. (NYSE:EBS) Shares Bought by Hodges Capital Management Inc.
Hodges Capital Management Inc. increased its position in Emergent Biosolutions, Inc. (NYSE:EBS) by 45.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 80,000 shares of the biopharmaceutical company’s stock after buying an additional 25,000 shares during the period. Hodges Capital Management Inc.’s holdings in Emergent Biosolutions were worth $2,713,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Emergent Biosolutions by 6.7% in the first quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock worth $109,574,000 after buying an additional 238,194 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Emergent Biosolutions by 1.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,053,683 shares of the biopharmaceutical company’s stock worth $59,639,000 after buying an additional 28,365 shares in the last quarter. Aberdeen Asset Management PLC UK increased its position in shares of Emergent Biosolutions by 29.6% in the first quarter. Aberdeen Asset Management PLC UK now owns 1,618,576 shares of the biopharmaceutical company’s stock worth $47,003,000 after buying an additional 369,908 shares in the last quarter. State Street Corp increased its position in shares of Emergent Biosolutions by 17.2% in the first quarter. State Street Corp now owns 1,452,472 shares of the biopharmaceutical company’s stock worth $42,180,000 after buying an additional 213,500 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of Emergent Biosolutions by 1.4% in the first quarter. Acadian Asset Management LLC now owns 1,400,091 shares of the biopharmaceutical company’s stock worth $40,658,000 after buying an additional 18,739 shares in the last quarter. 85.48% of the stock is owned by institutional investors.
Shares of Emergent Biosolutions, Inc. (EBS) opened at 35.16 on Wednesday. Emergent Biosolutions, Inc. has a 1-year low of $24.47 and a 1-year high of $36.81. The company’s 50 day moving average is $34.52 and its 200-day moving average is $31.31. The company has a market capitalization of $1.44 billion, a P/E ratio of 27.95 and a beta of 1.22.
Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by $0.13. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The company had revenue of $100.77 million during the quarter, compared to analyst estimates of $111.57 million. During the same quarter in the previous year, the business posted ($0.05) earnings per share. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities research analysts forecast that Emergent Biosolutions, Inc. will post $1.56 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Emergent Biosolutions, Inc. (NYSE:EBS) Shares Bought by Hodges Capital Management Inc.” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/09/emergent-biosolutions-inc-nyseebs-shares-bought-by-hodges-capital-management-inc.html.
A number of equities analysts have weighed in on EBS shares. BidaskClub downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $44.00.
In related news, Chairman Fuad El-Hibri sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $36.50, for a total value of $912,500.00. Following the completion of the transaction, the chairman now owns 1,630,216 shares in the company, valued at approximately $59,502,884. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 16.50% of the stock is owned by company insiders.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.